Cost-effectiveness of dual maternal HIV and syphilis testing strategies in high and low HIV prevalence countries: a modelling study. by Rodriguez, Patricia J et al.
Articles
www.thelancet.com/lancetgh   Vol 9   January 2021 e61
Cost-effectiveness of dual maternal HIV and syphilis testing 
strategies in high and low HIV prevalence countries: 
a modelling study
Patricia J Rodriguez, D Allen Roberts, Julianne Meisner, Monisha Sharma, Morkor Newman Owiredu, Bertha Gomez, Maeve B Mello, Alexey Bobrik, 
Arkadii Vodianyk, Andrew Storey, George Githuka, Thato Chidarikire, Ruanne Barnabas, Magdalena Barr-Dichiara, Muhammad S Jamil, 
Rachel Baggaley, Cheryl Johnson, Melanie M Taylor, Alison L Drake
Summary
Background Dual HIV and syphilis testing might help to prevent mother-to-child transmission (MTCT) of HIV and 
syphilis through increased case detection and treatment. We aimed to model and assess the cost-effectiveness of dual 
testing during antenatal care in four countries with varying HIV and syphilis prevalence.
Methods In this modelling study, we developed Markov models of HIV and syphilis in pregnant women to estimate 
costs and infant health outcomes of maternal testing at the first antenatal care visit with individual HIV and syphilis 
tests (base case) and at the first antenatal care visit with a dual rapid diagnostic test (scenario one). We additionally 
evaluated retesting during late antenatal care and at delivery with either individual tests (scenario two) or a dual rapid 
diagnosis test (scenario three). We modelled four countries: South Africa, Kenya, Colombia, and Ukraine. Strategies 
with an incremental cost-effectiveness ratio (ICER) less than the country-specific cost-effectiveness threshold (US$500 
in Kenya, $750 in South Africa, $3000 in Colombia, and $1000 in Ukraine) per disability-adjusted life-year averted 
were considered cost-effective.
Findings Routinely offering testing at the first antenatal care visit with a dual rapid diagnosis test was cost-saving 
compared with the base case in all four countries (ICER: –$26 in Kenya,–$559 in South Africa, –$844 in Colombia, 
and –$454 in Ukraine). Retesting during late antenatal care with a dual rapid diagnostic test (scenario three) was cost-
effective compared with scenario one in all four countries (ICER: $270 in Kenya, $260 in South Africa, $2207 in 
Colombia, and $205 in Ukraine).
Interpretation Incorporating dual rapid diagnostic tests in antenatal care can be cost-saving across countries with 
varying HIV prevalence. Countries should consider incorporating dual HIV and syphilis rapid diagnostic tests as the 
first test in antenatal care to support efforts to eliminate MTCT of HIV and syphilis.
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Introduction
Dual elimination of mother-to-child transmission (MTCT) 
of HIV and syphilis is a public health priority. Worldwide, 
1·4 million maternal HIV infections and 988 000 maternal 
syphilis infections occur annually.1 Although maternal 
treatment is highly effective at preventing MTCT of both 
HIV and syphilis, gaps in maternal testing and treat-
ment coverage lead to 180 000 infant HIV infections, 
355 000 adverse congenital syphilis birth outcomes, and 
306 000 non-clinical congenital syphilis cases every year.1,2 
WHO has set goals to reach elimination of MTCT of HIV 
and syphilis, including at least 95% of pregnant women 
receiving antenatal care, 95% tested for HIV and syphilis, 
and 95% treated for their infection(s).3–5 Yet, by 2020, only 
14 countries had received validation by WHO for achieving 
the elimination of paediatric HIV or congenital syphilis.1,6 
Globally, as HIV testing coverage has increased, more 
pregnant women with HIV are aware of their status, 
of whom 85% have accessed treatment; whereas, only 
66% of pregnant women are tested for syphilis, of whom 
78% receive treatment.1,7 Global efforts for prevention of 
MTCT (PMTCT) of HIV have led to substantial reductions 
in new paediatric HIV infections, but PMTCT of syphilis 
has received considerably less attention and success.1
Integrating syphilis testing and treatment into existing 
HIV PMTCT programmes might avert additional syphilis 
morbidity and mortality. 57% of congenital syphilis cases 
resulting in adverse birth outcomes were attributed to an 
absence of syphilis screening for women attending 
antenatal care.1 Testing coverage for HIV is often several 
times higher than for syphilis, suggesting that integrated 
testing could improve syphilis test coverage.8 Although 
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rapid diagnostic tests are standard for HIV, many 
countries still rely on laboratory-based testing for syphilis. 
Three dual HIV and syphilis rapid diagnostic tests, which 
allow concurrent antenatal care testing that circumvents 
laboratory testing obstacles for syphilis, are WHO 
prequalified.9
With restricted resources (including for programmes to 
support funding for staff training, time to offer testing, 
and test kits) and a need to prioritise highly effective 
interventions in resource-limited settings, policy makers 
need health economic evidence to decide where and how 
to implement dual HIV and syphilis testing. Dual HIV 
and syphilis testing in antenatal care has been shown to 
be a cost-effective approach in Malawi,9 but benefits and 
costs of this approach in diverse geographical regions 
with different health systems and HIV and syphilis 
burden have not been examined.
We aimed to compare the use of a dual rapid diagnostic 
test with individual tests at the first antenatal care visit 
and assess the effect of retesting for HIV and syphilis 
during pregnancy using a dual rapid diagnostic test. 
Many countries already retest for HIV during late 
antenatal care and delivery,10 and retesting for HIV 
during the third trimester is recommended by WHO in 
high HIV-burden settings and key populations;11 however, 
some low HIV-burden settings might also consider 
retesting in their efforts to achieve elimination of MTCT 
of HIV (Meisner J and Roberts DA, unpublished). The 
use of retesting for syphilis during pregnancy has not 
previously been reported for countries with varied HIV 
and syphilis prevalence.12,13
Methods
Model overview and testing scenarios
Using a Markov decision analytical model, we did a cost-
effectiveness analysis of maternal HIV and syphilis 
testing using individual tests and dual rapid diagnostic 
tests in Kenya, South Africa, Colombia, and Ukraine—
four countries that represent a range of HIV prevalence, 
syphilis prevalence, and geographical settings. Countries 
were classified as having low (<5%; Colombia and 
Ukraine), intermediate (5–15%; Kenya), and high (≥15%; 
South Africa) HIV prevalence.14 We compared four HIV 
and syphilis testing scenarios, varying the assay type and 
timing of testing (table 1). The primary analysis assessed 
the cost-effectiveness of dual HIV and syphilis testing 
compared with individual tests at the first antenatal care 
visit, and the secondary analysis evaluated the effect of 
retesting for HIV and syphilis during late antenatal care. 
We modelled the same test types across all four countries 
Research in context
Evidence before this study
Globally, HIV testing coverage is high during pregnancy; by 
contrast, syphilis testing coverage is frequently lower, but it 
could be increased if combined with HIV testing. As countries 
strive to achieve elimination of mother-to-child transmission 
of both infections, studies that identify strategies to efficiently 
optimise implementation of maternal HIV and syphilis testing 
are crucial to maximise the number of infant infections 
prevented. We searched PubMed for studies published from 
the inception of the database to July 28, 2020, with no 
language restrictions. Using the search terms “HIV infections” 
OR “HIV infections/transmission” OR “HIV” OR “syphilis, 
congenital” AND “mass screening” OR “screening”(tiab) OR 
“testing”(tiab) AND “repeat”(tiab) OR “retest”(tiab) AND 
“maternal”(tiab) OR “pregnancy” AND “cost-effectiveness” OR 
“cost-benefit analysis” OR “mass screening/economics” eight 
studies were found with this specific combination. Previous 
cost-effectiveness analyses of dual HIV and syphilis testing or 
syphilis retesting during pregnancy have focused on a single 
country. Dual HIV and syphilis testing was shown to be cost-
effective in Malawi and retesting for syphilis has shown mixed 
cost-effectiveness results in the USA. None of the previously 
published modelling analyses provided results relevant to a 
variety of contexts and settings. 
Added value of this study
To our knowledge, this is the first study to model the health 
and economic effects of using a single rapid diagnostic test for 
both HIV and syphilis in the context of antenatal care in 
multiple countries that represent diverse geographical and HIV 
and syphilis prevalence settings. To our knowledge, this 
exploratory analysis of retesting for syphilis and HIV using the 
dual rapid diagnostic test is the first analysis of the cost-
effectiveness of maternal retesting for syphilis outside the 
USA, and the first cost-effectiveness analysis of retesting using 
a dual rapid diagnostic test. 
Implications of all the available evidence
We find that using a dual rapid diagnostic test for HIV and 
syphilis at the first antenatal care visit is cost-saving compared 
with using a rapid HIV test and laboratory-based syphilis test in 
all four countries evaluated, regardless of HIV prevalence. Dual 
rapid diagnostic test for HIV and syphilis at the first antenatal 
care visit is projected to avert many congenital syphilis cases 
and disability-adjusted life-years, but similar numbers of infant 
HIV infections as independent HIV and syphilis tests.  Retesting 
in late pregnancy with a dual rapid diagnostic test was more 
effective and less costly than independent HIV and syphilis 
tests during late pregnancy. This analysis highlights potential 
health and economic benefits of integrating maternal HIV and 
syphilis testing. Programmes might consider incorporating 
dual rapid diagnostic tests for HIV and syphilis as a cost-
effective approach within antenatal care to improve maternal 
and infant health outcomes.
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because of heterogeneity within countries and to 
enable comparison between countries. We modelled 
the use of dual rapid diagnostic test and individual HIV 
and syphilis tests followed by confirmatory testing. 
We assumed HIV diagnoses followed two consecutive 
reactive rapid diagnostic tests. Individual syphilis testing 
was modelled as a laboratory-based rapid plasma reagin 
test with confirmatory testing for reactive results with 
the Treponema pallidum haemagglutination assay. No 
confirmatory test for syphilis was modelled for dual rapid 
diagnostic test scenarios.
In the base case scenario, we assumed that HIV and 
syphilis testing with individual tests was done at the first 
antenatal care visit, defined by country-specific average 
gestational age at the first visit. In scenario one, we 
modelled testing at the first antenatal care visit using a 
dual rapid diagnostic test. Additionally, because maternal 
HIV retesting is already recommended in many countries, 
we modelled two scenarios that incorporated maternal 
HIV retesting to address operational considerations. To 
estimate the relative health and economic effect attributed 
to HIV versus syphilis, we compared retesting with 
individual tests (scenario two) with retesting during late 
antenatal care and delivery with a dual rapid diagnostic 
test (scenario three). Retesting scenarios included women 
who missed HIV or syphilis testing at first antenatal care 
visit (ie, because they did not attend antenatal care before 
the gestational age when retesting would occur or because 
of gaps in test coverage). Retesting scenarios also allowed 
for HIV retesting at delivery for women not tested during 
late antenatal care (dual and individual tests), but not for 
syphilis retesting at delivery. For scenarios in which dual 
rapid diagnostic tests were modelled (scenarios one and 
three), we assumed that all women tested received the test 
regardless of previous HIV diagnosis or syphilis infection.
Model structure, parameterisation, and assumptions
Maternal HIV and syphilis were modelled using separate 
Markov models (appendix pp 1–2). The HIV model was 
adapted from a previous model of maternal HIV 
retesting, and reflects HIV prevalence, incidence, disease 
progression, and treatment during pregnancy and post 
partum using 54 Markov states (six maternal HIV states 
by nine antenatal and post partum periods; Meisner J and 
Roberts DA, unpublished). The congenital syphilis model 
reflects syphilis prevalence, incidence, testing, and 
treatment using eight maternal syphilis states with time-
varying transitions. We assumed risk of MTCT of HIV 
and syphilis and associated infant health outcomes were 
independent. Risk of infant HIV was modelled for 1 year 
after birth. The time step in both models was 1 week, and 
the time horizon was 20 years after birth—a common 
time horizon that allows our results to be directly 
compared with other cost-effectiveness analyses. The 
model was built in Microsoft Excel (2016).
Models were parametrised using values from the 
literature, in-country contacts, and expert opinion; 
country-specific estimates were used when available 
(table 2). Although HIV and syphilis models were 
constructed separately, they share common model 
parameter inputs. Both models incorporate disease 
prevalence, incidence, antenatal care attendance, test 
coverage, test sensitivity and specificity, maternal and 
infant mortality rates, and probability of infant infection. 
For each country, we modelled a population of pregnant 
women equal to the estimated number of annual 
pregnancies, or the number of livebirths if the number of 
pregnancies was unavailable. All pregnancies were 
assumed to be singleton. Fetal loss because of syphilis 
was modelled, but fetal loss because of HIV was not.
Health effect
We modelled infant HIV infection, congenital syphilis, 
and infant death. Infant HIV infections and deaths were 
estimated on the basis of total exposure to HIV in utero 
and post partum, with probabilities dependent on new 
versus established maternal HIV infection (on the basis of 
Fiebag stages), maternal viral suppression, maternal 
antiretroviral therapy (ART), infant ART, and breastfeeding 
practices. Congenital syphilis outcomes (stillbirth, neo-
natal death, preterm birth and low birthweight, clinical 
congenital syphilis, and non-clinical syphilis) were 
estimated at birth and modified by receipt and timing 
of adequate maternal syphilis treatment during preg-
nancy.15 We followed WHO guidelines on the definition of 
adequate syphilis treatment as at least 30 days before birth 
(modelled as ≤32 weeks) to prevent fetal infection, and 
set probabilities of adverse infant outcomes for later 
treatment equal to those for no treatment. We considered 
all infants born to untreated and late treated mothers 
to have congenital syphilis, regardless of symptoms.6 
We accounted for duplication of outcomes between the 
HIV and syphilis models by calculating infant co-
infection as the joint probability of syphilis and HIV 
infection in infants, assuming independence. Syphilis-
related stillbirths and neonatal deaths were subtracted 
from the population at delivery in the HIV model.
First ANC visit Late ANC visit 
Syphilis HIV Syphilis HIV
Base case RPR and TPHA Rapid No test No test
Scenario one Dual Dual No test No test
Scenario two RPR and TPHA Rapid RPR and TPHA Rapid
Scenario three Dual Dual Dual Dual
Base case used independent tests at country-specific timepoints. Scenario one used 
dual HIV and syphilis testing with no retesting during late ANC. Scenario two used 
independent HIV and syphilis tests with retesting during late ANC. Scenario three 
used dual HIV and syphilis testing with retesting during late ANC. Dual test is a 
single, point-of-care rapid test for HIV and syphilis. Independent tests include rapid 
HIV tests and laboratory-based syphilis tests (RPR and TPHA to confirm reactive 
results). Late ANC occurred from 36 to 39 weeks’ gestation. ANC=antenatal care. 
RPR=rapid plasma reagin. TPHA=Treponema pallidum haemagglutination assay.
Table 1: Dual HIV and syphilis testing models scenarios
See Online for appendix
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We converted infant infections and adverse birth 
outcomes into disability-adjusted life-years (DALYs; 
appendix pp 16–17).16 Total DALYs were the sum 
of years lived with disability and years of life lost up to 
the age of 20 years. We assumed DALYs for each 
stillbirth and neonatal death were equal. We used 
disability weights from the Global Burden of Disease 
study and stan dard formulas for calculating co-infection 
disability weights.16,17 For HIV-infected infants on ART at 
1 year, the disability weight for HIV while on ART was 
applied over the 20-year time horizon. For HIV-infected 
infants not on ART at 1 year, we assumed 90% of 
time was spent with symptomatic HIV and 10% with 
AIDS over the 20-year time horizon. For infants with 
congenital syphilis, the disability weight was applied 
only to the first 3 years of life. DALYs were discounted at 
3% annually.18
Costs and cost-effectiveness
We used a health-care system perspective for the model. 
Costs of supplies, labour, and treatment were obtained 
from the literature, in-country contacts, and expert 
Kenya South Africa Colombia Ukraine
Population of pregnant women 1 631 470 1 100 699 346 409 363 946 
HIV risk
HIV prevalence 6·1% 3·1% 0·4% 0·7%
Maternal HIV incidence rate (per person-week)
Before first ANC visit during pregnancy 0·000331 0·000227 0·00001 0·000002
Between first ANC visit and delivery 0·000331 0·000739 0·00002 0·000004
Delivery to 6 weeks post partum 0 0 0 0
6 weeks to 12 months post partum 0·000269 0·0009 0·00003 0·000003
Duration of incident maternal HIV infection (weeks) 9 9 9 9
HIV testing and prevention
Test kit unavailable 5·0% 5·0% 0·0% 0·0%
Test acceptance 84·0% 98·0% 89·0% 97·2%
Received test results 97·8% 98·0% 100·0% 100·0%
HIV rapid test sensitivity in early infection 66·7%  66·7% 66·7% 66·7%
HIV rapid test sensitivity in chronic infection 100·0% 100·0% 100·0% 100·0% 
HIV rapid test specificity 98·9% 98·9% 98·9% 98·9%
Dual test sensitivity in early infection 66·7%  66·7% 66·7% 66·7%
Dual test sensitivity in chronic infection 100·0% 100·0% 100·0% 100·0%
Dual test specificity 98·9% 98·9% 98·9% 98·9%
MTCT rate per week, acute maternal infection 0·005–0·029 0·005–0·029 0·005–0·029 0·005–0·029
MTCT rate per week, chronic maternal infection 0·0005–0·023 0·0005–0·023 0·0005–0·023 0·0005–0·023
Maternal PrEP use 0·0% 0·0% 0·0% 0·0%
Health-care visits
Attended first ANC visit 96·0% 94·0% 97·4% 99·8% 
Attended late ANC visit 92·7% 78·0% 88·1% 90·0%
Facility delivery 61·8% 96·0% 98·9% 99·0% 
Gestational age at first ANC visit (weeks) 22 18 15 10
Gestational age at late ANC visit (weeks) 33 36 24 28
Gestational age at delivery (weeks) 39 39 39 39
ARV coverage
Maternal ART use 91·0% 87·0% 87·8% 95·0%
Virally suppressed women with HIV 88·1% 72·0% 88·4% 88·1% 
Weekly ART dropout (%) 0·3% 0·3% 0·3% 0·3%
HIV-exposed infants receiving ARVs 93·6% 98·7% 96·0% 98·4%
HIV-infected infants receiving ART* 61·0% 63·0% 57·9% 95·0%
Breastfeeding
Not breastfeeding in early post partum (0–6 weeks) 2·5% 34·0% 97·9% 95·0%
Not breastfeeding in mid post partum (6 weeks to 
6 months)
21·2% 45·0% 97·9% 99·0%
Not breastfeeding in late post partum (6–12 months) 33·4% 63·0% 97·9% 99·0%
(Table 2 continues on next page)
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opinion (appendix pp 18–30). Empirical time-motion data 
collected in Kenya were used to calculate HIV testing 
costs in the country and estimates of time to testing were 
applied to other regions with country-specific labour 
and supply costs. Only incremental costs associated 
with testing and treatment were included. We excluded 
Kenya South Africa Colombia Ukraine
(Continued from previous page)
Maternal mortality rate (per person-week)
During pregnancy 0·0001 0·0001 0·00002 0·00002
Delivery to 6 weeks post partum 0·0006 0·0002 0·0001 0·00003
6 weeks to 12 months post partum 0·0001 0·0001 0·00002 0·00002
Neonatal and infant mortality (per person-week) and survival
Stillbirth, syphilis positive (mother not treated) 21·0% 21·0% 21·0% 21·0%
Stillbirth, syphilis positive (mother treated) 3·8% 3·8% 3·8% 3·8%
Neonatal mortality, birth to 6 weeks (mother had syphilis 
and not treated)
9·0% 9·0% 9·0% 9·0%
Neonatal mortality, birth to 6 weeks (mother had syphilis 
and treated)
1·8% 1·8% 1·8% 1·8%
Neonatal mortality, birth to 6 weeks (syphilis negative 
and HIV negative or HIV negative and on ART)
0·5% 0·3% 0·2% 0·1%
Infant mortality, >6 weeks to 12 months 0·03% 0·03% 0·01% 0·01%
Survival to 1 year, HIV negative or HIV positive and on ART 96·4% 96·7% 98·7% 99·2% 
Survival to 1 year, HIV positive and not on ART 64·8% 64·8% 64·8% 64·8%
Syphilis
Syphilis prevalence 1·2% 2·0% 0·41% 2·5%
Maternal syphilis incidence rate (per person-week) 0·00008 0·00008 0·00004 0·000015
Laboratory-based test sensitivity for syphilis 80·0% 80·0% 80·0% 80·0%
Laboratory-based test specificity for syphilis 100·0% 100·0% 100·0% 100·0%
Dual RDT sensitivity for syphilis 87·0% 87·0% 87·0% 87·0%
Dual RDT specificity for syphilis 99·5% 99·5% 99·5% 99·5%
Test correction factor† 52·9% 52·9% 52·9% 52·9%
Test coverage (laboratory-based testing)‡ 73·0% 83·0% 62·8% 98·0%
Received treatment (laboratory-based testing) 50·0% 90·0% 90·8% 99·0%
Received treatment (dual testing) 62·5% 92·5% 93·1% 99·3%
HIV costs (US$)
Third generation rapid screening per woman $2·64 $7·72 $6·68 $3·99
True-positive screening tests per woman* $3·68 $11·39 $8·53 $4·18
False-positive screening tests per woman* $26·39 $34·17 $74·83 $19·80
Maternal ART, per week per woman $4·86 $4·79 $18·89 $32·84
Infant ARV prophylaxis (total cost) per infant $2·32 $3·82 $52·10 $4·00
Maternal PrEP, per week per woman $6·19 $6·19 $18·89 $19·38
Infant ART, per week per infant $6·73 $5·46 $18·89 $32·84
Syphilis costs 
RPR test screening per woman $3·09 $9·32 $6·92 $0·63
TPHA test screening per woman $0·59 $3·04 $3·43 $1·14
Dual test screening per woman $5·79 $8·69 $8·21 $1·99
Benzathine benzylpenicillin injection, maternal treatment 
per woman
$0·64 $0·60 <$0·01 $3·00
Intravenous benzathine benzylpenicillin, infant treatment 
per infant
$1·42 $1·42 $1·42 $1·42
Paediatric inpatient, per day per infant $8·41 $72·81 $62·87 $28·84
Details and sources provided in appendix (pp 18–30). All costs reported in 2017 US$. ANC=antenatal care. ART=antiretroviral therapy. ARV=antiretrovirals. MCH=maternal 
and child health. MTCT=mother-to-child transmission. PrEP=pre-exposure prophylaxis. RDT=rapid diagnostic test. RPR=rapid plasma reagin. TPHA=Treponema pallidum 
hemagglutination assay. *Based on the percent of infants with early infant diagnosis. †Test correction factor is the probability that a woman who tested positive for syphilis 
has an active syphilis infection. ‡Inclusive of stock-outs.
Table 2: Key model parameters
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start-up costs (eg, training) and distribution costs. Costs 
given in local currency units were converted to US$ using 
exchange rates from June of the year they were collected. 
All costs were adjusted to 2017 US$ using the US gross 
domestic product deflator and discounted at 3% annually.19
The incremental cost-effectiveness ratio (ICER)—
defined as the incremental costs divided by DALYs 
averted—was calculated by comparing scenario one (dual 
test at first antenatal care visit) with the base case. Retesting 
scenarios were compared with the next-best scenario (by 
DALYs). Dominated scenarios, those that were more costly 
and less effective than an alternative, were excluded from 
calculations.20 ICERs less than the country-specific cost-
effectiveness threshold were con sidered cost-effective. 
We used the following thresholds based on estimated 
opportunity cost of health investment foregone: US$500 
(Kenya),21,22 $750 (South Africa),23 $1000 (Ukraine),24 and 
$3000 (Colombia)25 per DALY averted.
Sensitivity analysis
Uncertainty analyses were done for scenario one. 
One-way sensitivity analyses were used to assess the 
effect of changing individual model parameters, inc lu-
ding HIV and syphilis prevalence, test coverage, test 
characteristics, gestational age at first antenatal care visit, 
and costs. We used low and high parameter values from 
confidence interval bounds for test characteristics, and 
20% relative changes for all other parameters. We also 
did scenario implementation analyses to estimate the 
effect of epidemic changes (declines in HIV and syphilis 
prevalence) or HIV test acceptance on cost-effectiveness, 
calculated using Microsoft Excel (2016).
Role of the funding source
Collaborators from WHO were involved in study design, 
interpretation of results, and manuscript development; 
no other funders had a role in design, analysis, or 
interpretation. All collaborators had full access to all the 
data in the study. ALD had final responsibility for the 
decision to submit for publication, with concurrence 
from all authors. 
Results
We modelled populations of 1 631 470 pregnant women in 
Kenya, 1 100 699 in South Africa, 346 409 in Colombia, 
and 363 946 in Ukraine. In our models, routinely offering 
a dual HIV and syphilis rapid diagnostic test at the first 
antenatal care visit (scenario one) was more effective 












Base case $62 924 984 13 468 18 832 1 030 415 ··  ·· ·· ··
Scenario one $62 671 902 13 470 15 827 1 020 644 –$253 082 9770 –$26‡ Base case
Scenario two $67 356 499 10 943 18 832 1 015 467 $4 684 597 5177 Dom ··
Scenario three $66 707 622 10 944 15 827 1 005 693 $4 035 720 14 951 $270§ Scenario one
South Africa
Base case $151 601 450 27 012 12 257 745 434 ··  ·· ·· ··
Scenario one $146 367 385 27 017 9348 736 077 –$5 234 065 9358 –$559‡ Base case
Scenario two $162 156 341 23 829 12 257 727 129 $15 788 956 8947 Dom ··
Scenario three $151 135 725 23 834 9348 717 766 $4 768 340 18 311 $260§ Scenario one
Colombia
Base case $5 855 930 145 1281 73 133 ··  ·· ·· ··
Scenario one $4 794 810 145 878 71 875 –$1 061 120 1258 –$844‡ Base case
Scenario two $9 279 059 122 916 71 842 $4 484 248 33 Dom ··
Scenario three $7 295 786 122 564 70 742 $2 500 976 1133 $2207§ Scenario one
Ukraine
Base case $8 801 528 71 2333 54 818 ··  ·· ·· ··
Scenario one $7 902 302 71 1694 52 837 –$899 226 1980 –$454‡ Base case
Scenario two $10 327 010 67 890 50 432 $2 424 707 2405 Dom ··
Scenario three $8 588 217 67 593 49 486 $685 914 3352 $205§ Scenario one
Base case used independent tests specific to each setting. Scenario one used dual HIV and syphilis testing with no retesting during late ANC. Scenario two used independent 
HIV and syphilis tests with retesting during late ANC. Scenario three used dual HIV and syphilis testing with retesting during late ANC. ANC=antenatal care. DALY=disability-
adjusted life-year. ICER=incremental cost-effectiveness ratio. Dom=dominated (more costly and less effective than dominating scenario). *DALYs averted and incremental 
costs are compared with the next most effective (by DALYs) scenario. Individual tests are HIV rapid tests and rapid plasma regain tests for syphilis; Treponema pallidum 
hemagglutination assay used for confirmatory syphilis testing for reactive rapid plasma regain results. Reactive rapid HIV tests and dual HIV tests confirmed with an 
additional HIV rapid test. †Calculated as incremental costs (in 2017 US$) divided by DALYs averted compared with the next most effective (by DALYs) scenario, with 
dominated scenarios removed. ‡Indicates scenario is cost-saving. §Indicates scenario is cost-effective compared to country-specific cost-effectiveness threshold. 
Table 3: Health effect and cost-effectiveness of maternal HIV and syphilis testing scenarios
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and less costly compared with individual HIV rapid diag-
nostic tests and laboratory assays for syphilis in all 
four countries (table 3). Per DALY averted, a dual rapid 
diagnostic test at the first antenatal care visit saved $26 in 
Kenya, $559 in South Africa, $844 in Columbia, and 
$545 in Ukraine. Dual rapid diagnostic tests at the first 
antenatal care visit averted 3005 congenital syphilis cases 
in Kenya, 2909 in South Africa, 403 in Colombia, and 
639 in Ukraine and reduced DALYs by 9770 in Kenya, 
9358 in South Africa, 1258 in Colombia, and 1980 in 
Ukraine. The PMTCT potential for HIV using the dual 
rapid diagnostic test and independent tests was similar 
in Ukraine and Columbia but resulted in more HIV 
infections in Kenya (one) and South Africa (five).
Retesting in late pregnancy with a dual rapid diagnostic 
test (scenario three) was more effective and less costly 
than retesting in late pregnancy with individual tests 
(scenario two). Retesting with a dual rapid diagnostic test 
averted 2526 additional HIV infections in Kenya and 
3184 in South Africa compared with testing with the rapid 
diagnostic test only at the first antenatal care visit (scenario 
one). Retesting with the dual rapid diagnostic test was 
cost-effective in all countries (ICER in Kenya $270, 
South Africa $260, Colombia $2207, and Ukraine $205). 
However, in countries with low HIV prevalence, fewer 
additional HIV cases were averted by retesting in 
Colombia (23) and Ukraine (four). When retesting 
occurred by 32 weeks, 352 additional congenital syphilis 
cases were averted in Colombia and 297 were averted in 
Ukraine. By contrast, retesting did not avert any additional 
congenital syphilis cases in Kenya or South Africa because 
testing was done after 32 weeks.
The findings from scenario one were most sensitive 
to gestational age at first antenatal care visit, syphilis 
test coverage, overall cost of testing with dual rapid 
diagnostic tests, and HIV test acceptance, but were robust 
to parameter uncertainty (figure 1). ICER out comes in 
South Africa were particularly sensitive to syphilis testing 
coverage, which varied between 66% and 100%; by 
contrast, we varied coverage in Kenya between 58% and 
88%. Although ICERs were below the cost-effectiveness 
threshold in all one-way sensitivity analyses, ICER values 
for Kenya moved from cost-saving to cost-effective when 
gestational age at the first antenatal care visit, overall 
testing cost for the dual rapid diagnostic test, HIV test 
acceptance, syphilis testing coverage, and overall testing 
Figure 1: One-way sensitivity analysis for scenario one in Kenya (A), South Africa (B), Columbia (C), and Ukraine (D)
Scenario one used dual HIV and syphilis testing with no retesting during late ANC. One-way sensitivity plots, comparing scenario one with the base case under high and low alternative parameter values. High 
and low bound represent CI bounds for available test characteristics, and 20% relative changes for all other modelled parameter values. For each country the plot contains the ten parameters to which 
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cost per rapid plasma regain were modified. In Colombia, 
ICERs were most sensitive to HIV test acceptance, syphilis 
testing coverage, and overall testing costs for the dual 
rapid diagnostic test, HIV rapid diagnostic test, and rapid 
plasma reagin tests. In Ukraine, ICERs were most 
sensitive to changes to dual rapid diagnostic test sensitivity 
for syphilis and syphilis testing coverage.
Cost-effectiveness of various strategies were also robust 
to decreases in maternal HIV and syphilis prevalence, 
and changes in HIV testing coverage across scenarios 
and countries (figure 2). ICERs were most sensitive to 
changes in HIV testing coverage and decreases in HIV 
prevalence in settings of intermediate (Kenya) and high 
(South Africa) HIV prevalence.
Discussion
Our model-based analysis projected that incorporating a 
dual HIV and syphilis rapid diagnostic test at the first 
antenatal care visit is cost-saving in settings of high 
(South Africa), intermediate (Kenya), and low (Colombia 
and Ukraine) HIV prevalence, compared with using 
individual HIV and syphilis tests. Overall, our results 
suggest syphilis test coverage in antenatal care could 
increase if dual rapid diagnostic tests are used and that 
dual tests have the potential to overcome any limitations, 
such as the time to do individual HIV or syphilis tests. 
Conclusions were consistent across a range of settings 
with varied maternal syphilis prevalence (0·41–2·5%), 
and the results are consistent with a previous analysis 
from Malawi.9 Compared with individual tests for HIV 
and syphilis, dual HIV and syphilis testing at the first 
antenatal care visit averted congenital syphilis infections 
and DALYs, but it led to small increases in the absolute 
number of infant HIV infections in Kenya and South 
Africa. Increases in infant HIV infections are attributed 
to increased infant survival when syphilis-related stillbirth 
and neonatal deaths were averted, leading to a larger 
population of infants at risk for HIV.
Kenya South Africa































































Dual test at first and late ANC visits
Country
F





















Dual test at first and late ANC visits
C




















Dual test at first and late ANC visits
D
HIV testing coverage scenarios
Syphilis prevalence scenarios



















Dual test at first and late ANC visits
A





















Dual test at first and late ANC visits
BHIV prevalence scenarios
Figure 2: Scenario implementation analyses
(A) Decreasing HIV prevalence in Kenya and South Africa. (B) Decreasing HIV prevalence in Colombia and Ukraine. (C) Decreasing syphilis prevalence in Kenya and South Africa. (D) Decreasing syphilis 
prevalence in Colombia and Ukraine. (E) Variation in HIV testing acceptance in Kenya and South Africa. (F) Variation in HIV testing acceptance in Colombia and Ukraine.  Base case used independent tests 
at country-specific timepoints. Scenario one used dual HIV and syphilis testing with no retesting during late ANC. Scenario two used independent HIV and syphilis tests with retesting during late ANC. Scenario three 
used dual HIV and syphilis testing with retesting during late ANC. ICERs compare scenario one with the base case and scenario three with scenario one, under alternative parameter values. ANC=Antenatal 
care. DALY=disability-adjusted life-year. ICER=incremental cost-effectiveness ratio.
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In all countries, scenario three, which used a dual rapid 
diagnostic test at the first antenatal care visit and for 
retesting, was less costly and more effective than scenario 
two, which used individual tests at the same timepoints. 
Cost savings were primarily driven by lower costs per 
woman tested with a dual rapid diagnostic test at the first 
antenatal care visit compared with combined overall costs 
of testing with individual assays. In all countries except 
Kenya, a dual rapid diagnostic test kit was less expensive 
than the combined cost of an HIV rapid diagnostic test 
kit and a rapid plasma reagin test. Furthermore, testing 
with dual rapid diagnostic tests reduced labour costs in 
all countries. Although the dual rapid diagnostic test 
remained cost-effective with 20% increases in test kit cost, 
it was not always cost saving.
Because retesting did not avert additional syphilis 
infections in countries with intermediate and high HIV 
prevalence and antenatal care visits occurred after 32 weeks 
in these settings, retesting for HIV only (not modelled) is 
likely to be similarly effective and less costly than retesting 
with a dual rapid diagnostic test. In a previous analysis of 
the maternal HIV retesting model used for this analysis, 
retesting averted few infant HIV infections and has 
restricted potential for the prevention of MTCT of HIV in 
low HIV prevalence countries (Meisner J, unpublished 
data). Although retesting for maternal syphilis is not 
recommended by WHO, if retesting occurs early enough 
for maternal syphilis treatment to prevent adverse birth 
outcomes (≤32 weeks), it has the potential to avert 
stillbirths and congenital syphilis cases attributed to 
incident maternal syphilis infections or infections not 
previously detected. Our results suggest that retesting in 
countries with low HIV prevalence would avert few HIV 
infections and no congenital syphilis infections.
Operationally, retesting using dual HIV and syphilis 
rapid diagnostic tests might have advantages for 
simplifying testing algorithms that avoid laboratory-
based syphilis tests and reducing prices through 
increasing procurement volumes in high HIV-burden 
settings. However, challenges exist for the allocation of 
restricted resources towards a costly retesting strategy 
with minimal benefits. Programmes will need to clarify 
unique needs for women previously diagnosed with 
HIV who only require syphilis testing, and for those 
diagnosed with syphilis during their current pregnancy 
who require only HIV testing. Although many PMTCT 
programmes use HIV rapid diagnostic tests, laboratory 
testing for syphilis is still common in many low-income 
and middle-income settings. The logistics of laboratory 
testing for syphilis—such as sample collection following 
antenatal care visits and delays in waiting for laboratory 
results (eg, confirmatory assays for reactive tests)—
might result in women not getting tested, not receiving 
test results, lower syphilis treatment coverage, and more 
congenital syphilis cases.
Dual HIV and syphilis rapid diagnostic tests have many 
characteristics that appeal to individuals accessing services 
and health-care providers. They only require a single 
blood draw and provide immediate results, allowing 
health-care providers to make life-saving decisions 
regarding treat ment more quickly.26 Training for health-
care providers would be simplified because of the need for 
only one initial screening test for HIV and syphilis, rather 
than two. Additionally, dual rapid diagnostic tests have 
the advantage of streamlined procurement of test kits 
and reagents. However, countries will still need a supply 
of single HIV rapid diagnostic tests to avoid syphilis 
retesting when not indicated, to comply with national 
testing policies, to prevent missed opportunities to detect 
maternal HIV or syphilis infection, and to prevent MTCT 
in the event of dual rapid diagnostic test stock-outs. This 
could result in challenges determining which programmes 
should fund test kits, with siloed funding streams for HIV 
and syphilis. In addition, the sensitivity and specificity of 
the syphilis component of the dual assay has been 
reported to be variable under field conditions, and quality 
control measures should be followed to ensure accurate 
interpretation of results.27
Our analysis should be viewed in the context of some 
limitations. Syphilis testing in antenatal care might be 
heterogeneous between and within countries, and the 
assumption that countries exclusively use laboratory-
based syphilis testing might be inaccurate. There could be 
variation in the assay type within a country based on 
geographical differences or programmatic partners. Our 
results might have restricted generalisability to settings 
currently using rapid diagnostic tests for syphilis, and are 
subject to market prices for syphilis and HIV test kits and 
labour costs. Our retesting scenarios include women who 
are tested for the first time during late antenatal care, 
which might overstate the benefit of the retest relative to 
the first test. Because of the separate construction of the 
HIV and syphilis models, we were unable to model 
syphilis and HIV co-infection, and did not model risk of 
fetal loss due to HIV. However, whether risks of MTCT of 
HIV are higher in the context of maternal co-infection is 
unclear.26,28–30 Additionally, because of the small amount of 
data on the effectiveness of treating maternal syphilis 
infection after 32 weeks’ gestation, we assumed that there 
would not be an effect on PMTCT of syphilis after this 
point, which might underestimate maternal and infant 
benefits of retesting later in pregnancy. We also restricted 
syphilis-related disability to the first 3 years of life, which 
probably underestimates the burden of congenital 
syphilis. Adding additional years of disability from 
congenital syphilis would increase the positive health 
effect of dual testing. Although we used the literature and 
in-country experts to populate model parameters, some 
parameters were unavailable or based on a small amount 
of data, particularly related to syphilis. Future studies 
are needed to inform assumptions about breastfeeding 
practices, syphilis treatment coverage, and rates of adverse 
maternal syphilis outcomes. Our results were qualitatively 
robust to all one-way sensitivity analyses, but ICER 
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estimates might be imprecise. We had insufficient data to 
inform many parameter distributions and therefore did 
not do probabilistic sensitivity analysis to estimate credible 
intervals. Despite the limitations, our results are probably 
conservative estimates because we did not include 
maternal treatment benefits, such as improved quality of 
life, reduced risk of sexual trans mission, or health system 
costs averted. Our estimate of time to complete a rapid 
test of 30 min per patient might be conservative in some 
settings. Our analysis has several strengths. We included 
countries that represented variations in HIV prevalence, 
syphilis prevalence, and geographical region. We com-
pared HIV and syphilis testing strategies across countries 
using the same methods and model structure, and similar 
assumptions. Our analysis expanded on previous studies9 
by including incident syphilis and HIV infections, in 
addition to prevalent infections.
Dual HIV and syphilis rapid diagnostic test as the first 
test in antenatal care can improve efforts to provide 
integrated services within the antenatal care setting, 
saving overall costs while improving health outcomes 
for women and their children. Breaking down siloes 
of vertical programmes can improve the quality of 
antenatal care and help to streamline service delivery, 
thereby accelerating progress on efforts to achieve dual 
elimination of MTCT of HIV and syphilis.
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